Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Wang, Yongchao, Fiskus, Warren, Chong, Daniel G., Buckley, Kathleen M., Natarajan, Kavita, Rao, Rekha, Joshi, Atul, Balusu, Ramesh, Koul, Sanjay, Chen, Jianguang, Savoie, Andrew, Ustun, Celalettin, Jillella, Anand P., Atadja, Peter, Levine, Ross L., Bhalla, Kapil N.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2009
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788976/
https://ncbi.nlm.nih.gov/pubmed/19828702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222133
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы